Kilitch Drugs (India) (KILITCH) Fundamentals 2026 — P/E 20.0x, Revenue Analysis | SniperIQ
Kilitch Drugs (India) (KILITCH) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹623 Crore, trading at ₹178.18 on the NSE. This SniperIQ fundamentals page covers Kilitch Drugs (India)'s valuation (P/E 20.0x, P/B 2.2x), profitability (net margin 12.8%), revenue (₹235 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kilitch Drugs (India)'s market cap?
Kilitch Drugs (India) (KILITCH) has a market capitalization of approximately ₹623 Crore, trading at ₹178.18 on the NSE. Market cap moves with the live share price.
What is Kilitch Drugs (India)'s P/E ratio?
Kilitch Drugs (India)'s trailing twelve-month P/E ratio is 20.0x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kilitch Drugs (India)?
Kilitch Drugs (India) runs a net profit margin of 12.8%, a gross margin of 40.0%, and an operating margin of 14.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kilitch Drugs (India) generate?
Kilitch Drugs (India) reported revenue of ₹235 Crore for fiscal year 2026, with net income of ₹30 Crore and earnings per share (EPS) of 8.91. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kilitch Drugs (India) pay a dividend?
Kilitch Drugs (India) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Kilitch Drugs (India) financially healthy?
Kilitch Drugs (India) carries a debt-to-equity ratio of 0.32x and a current ratio of 1.83x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kilitch Drugs (India) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kilitch Drugs (India) (KILITCH) the key facts are: market cap ₹623 Crore, P/E 20.0x, revenue ₹235 Crore, 52-week range 117.25-227.225. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kilitch Drugs (India)'s full fundamentals live
Get Kilitch Drugs (India)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.